Working closely with Commercial Excellence, Medical Excellence, Information Systems, Data Solutions, Enterprise Architecture, and external partners, this leader will design scalable solutions that accelerate delivery, improve platform utilization, reduce technical debt, and create a modern, integrated experience for field teams. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.